Patents by Inventor Zaijun Zhang

Zaijun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11903923
    Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: February 20, 2024
    Inventors: Yuqiang Wang, Lipeng Xu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Peng Yi
  • Publication number: 20220371987
    Abstract: The present invention provided a process for manufacture of amantadine nitrate derivatives, and the process comprises using adamantane as the raw material to prepare amantadine nitrate derivatives via the following steps: (1) synthesis of adamantanol; (2) carboxylation of adamantanol; (3) acetylation of adamantanoic acid; (4) reduction; (5) hydrolysis of amido adamantanol and Boc protection of amino group; (6) crystallization of Boc protected amantadinol; (7) nitrate esterification of Boc protected amantadinol; (8) refining of the product of nitrate esterification; (9) Boc deprotection and salt formation; and (10) refining of amantadine nitrate hydrochloride. The amantadine nitrate derivatives have the struction of: wherein, R1 and R2 are each independently hydrogen, straight-chain or branched-chain alkyl, or substituted or unsubstituted aryl or heteroaryl. The process of this invention is efficient, cost effective, environmentally friendly, safe, reliable, and suitable for industrial production.
    Type: Application
    Filed: September 11, 2019
    Publication date: November 24, 2022
    Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang WANG, Zheng LIU, Yewei SUN, Zaijun ZHANG, Gaoxiao ZHANG
  • Publication number: 20220202812
    Abstract: The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I). Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and/or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.
    Type: Application
    Filed: November 3, 2021
    Publication date: June 30, 2022
    Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
  • Patent number: 11197855
    Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: December 14, 2021
    Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
  • Patent number: 11161800
    Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (II). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 2, 2021
    Inventors: Yuqiang Wang, Zheng Liu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Luchen Shan, Peng Yi, James Larrick
  • Patent number: 10703729
    Abstract: The present invention relates to a pyrazine derivative, and preparation method and medical use thereof. The pyrazine derivative can remove free radicals and suppress calcium overload and has cytoprotective effects, and can be used for the prevention and treatment of cardiovascular and cerebrovascular diseases, neurodegenerative diseases and other related diseases.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: July 7, 2020
    Inventors: Yuqiang Wang, Pei Yu, Yewei Sun, Luchen Shan, Gaoxiao Zhang, Zaijun Zhang, Peng Yi
  • Patent number: 10703730
    Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and medical uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 7, 2020
    Inventors: Yuqiang Wang, Haiyun Chen, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Yewei Sun, Luchen Shan, Liang Tao
  • Publication number: 20200155548
    Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 21, 2020
    Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
  • Publication number: 20190276413
    Abstract: The present invention relates to a pyrazine derivative, and preparation method and medical use thereof. The pyrazine derivative can remove free radicals and suppress calcium overload and has cytoprotective effects, and can be used for the prevention and treatment of cardiovascular and cerebrovascular diseases, neurodegenerative diseases and other related diseases.
    Type: Application
    Filed: July 4, 2016
    Publication date: September 12, 2019
    Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang WANG, Pei YU, Yewei SUN, Luchen SHAN, Gaoxiao ZHANG, Zaijun ZHANG, Peng YI
  • Publication number: 20190218192
    Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and medical uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Application
    Filed: March 19, 2019
    Publication date: July 18, 2019
    Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang Wang, Haiyun Chen, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Yewei Sun, Luchen Shan, Liang Tao
  • Publication number: 20190202772
    Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (II). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 4, 2019
    Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang WANG, Zheng LIU, Pei YU, Yewei SUN, Zaijun ZHANG, Gaoxiao ZHANG, Luchen SHAN, Peng YI, James LARRICK
  • Patent number: 10308616
    Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 4, 2019
    Inventors: Yuqiang Wang, Haiyun Chen, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Yewei Sun, Luchen Shan, Liang Tao
  • Patent number: 10214478
    Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: February 26, 2019
    Inventors: Yuqiang Wang, Zheng Liu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Luchen Shan, Peng Yi, James Larrick
  • Publication number: 20180346430
    Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Application
    Filed: August 11, 2015
    Publication date: December 6, 2018
    Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang WANG, Haiyun CHEN, Zaijun ZHANG, Gaoxiao ZHANG, Pei YU, Yewei SUN, Luchen SHAN, Liang TAO
  • Patent number: 10011555
    Abstract: This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: July 3, 2018
    Assignee: University of Macau
    Inventors: Ming Yuen Lee, Zaijun Zhang, Guohui Li
  • Publication number: 20180148404
    Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.
    Type: Application
    Filed: November 28, 2016
    Publication date: May 31, 2018
    Applicant: Guangzhou Magpie Pharmaceuticals Co., Ltd.
    Inventors: Yuqiang Wang, Zheng Liu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Luchen Shan, Peng Yi, James Larrick
  • Publication number: 20180147181
    Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 4, 2016
    Publication date: May 31, 2018
    Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.
    Inventors: Yuqiang Wang, Lipeng Xu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Peng Yi
  • Publication number: 20180065912
    Abstract: This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.
    Type: Application
    Filed: October 9, 2017
    Publication date: March 8, 2018
    Inventors: Ming Yuen LEE, Zaijun ZHANG, Guohui LI
  • Publication number: 20160376216
    Abstract: This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Inventors: Ming Yuen LEE, Zaijun ZHANG, Guohui LI
  • Patent number: 9486440
    Abstract: The present invention provides a method of using indole-ketone or indolidone such as SU4312, SU5416, SU11248 (Sunitinib), or indirubin-3-oxime to treat a neurodegenerative disease or disorder such as Parkinson's disease which is associated with excessive neuronal Nitric Oxide Synthase (nNOS) activity.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: November 8, 2016
    Assignees: UNIVERSITY OF MACAU, THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Ming Yuen Lee, Yifan Han, Chung Lit Choi, Zaijun Zhang, Wei Cui